Peter Ellmark

1 – 10 of 53

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/person/immt-pel?embed=1&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

« previous
1
2
3
4
5
6
next »

2025
Mark First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
Carneiro, Ana ^LU ; Hahn, Amanda ; Ellmark, Peter ^LU ; Enell Smith, Karin ^LU ; Schultz, Lena ; Ambarkhane, Sumeet ; Yachnin, Jeffrey and Ullenhag, Gustav J (2025) In Journal for ImmunoTherapy of Cancer 13.
- Contribution to journal › Article
2024
Mark Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes
Sincic, Viktor ^LU ; Arlenhold, Ken F. ; Richtmann, Sarah ^LU ; Lilljebjörn, Henrik ^LU ; Eriksson, Pontus ^LU ; Sjödahl, Gottfrid ^LU ; Wokander, Mats ; Hägerbrand, Karin ^LU ; Ellmark, Peter ^LU and Fioretos, Thoas ^LU , et al. (2024) In Cells 13(11).
- Contribution to journal › Article
Mark Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1) : a single-arm, multicentre phase 1b/2 study
Van Laethem, Jean Luc ; Borbath, Ivan ; Prenen, Hans ; Geboes, Karen Paula ; Lambert, Aurélien ; Mitry, Emmanuel ; Cassier, Philippe Alexandre ; Blanc, Jean Frédéric ; Pilla, Lorenzo and Batlle, Jaime Feliu , et al. (2024) In The Lancet Oncology 25(7). p.853-864
- Contribution to journal › Article
Mark Next-generation CD40 agonists for cancer immunotherapy
Andersson, Hampus ^LU ; Nyesiga, Barnabas ; Hermodsson, Tova ^LU ; Enell Smith, Karin ; Hägerbrand, Karin ; Lindstedt, Malin ^LU and Ellmark, Peter ^LU (2024) In Expert Opinion on Biological Therapy 24(5). p.351-363
- Contribution to journal › Scientific review
2023
Mark The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
Nelson, Michelle H. ; Fritzell, Sara ^LU ; Miller, Robert ; Werchau, Doreen ; Van Citters, Danielle ; Nilsson, Anneli ; Misher, Lynda ; Ljung, Lill ; Bader, Robert and Deronic, Adnan ^LU , et al. (2023) In Molecular Cancer Therapeutics 22(1). p.89-101
- Contribution to journal › Article
Mark ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
Enell Smith, Karin ; Fritzell, Sara ; Nilsson, Anneli ; Barchan, Karin ; Rosén, Anna ; Schultz, Lena ; Varas, Laura ; Säll, Anna ; Rose, Nadia and Håkansson, Maria , et al. (2023) In Cancer Immunology, Immunotherapy 72(12). p.4145-4159
- Contribution to journal › Article
Mark Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
Andersson, Hampus ^LU ; Sobti, Aastha ^LU ; Jimenez, David Gomez ^LU ; de Coaña, Yago Pico ; Ambarkhane, Sumeet Vijay ; Hägerbrand, Karin ^LU ; Smith, Karin Enell ; Lindstedt, Malin ^LU and Ellmark, Peter ^LU (2023) In Cells 12(19).
- Contribution to journal › Article
2022
Mark Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
Hägerbrand, Karin ^LU ; Varas, Laura ^LU ; Deronic, Adnan ^LU ; Nyesiga, Barnabas ; Sundstedt, Anette ^LU ; Ljung, Lill ; Sakellariou, Christina ^LU ; Werchau, Doreen ; Thagesson, Mia and Gomez Jimenez, David ^LU , et al. (2022) In Journal for ImmunoTherapy of Cancer 10(11).
- Contribution to journal › Article
Mark Transcriptional profiling demonstrates altered characteristics of CD8 + cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia
Abolhalaj, Milad ^LU ; Sincic, Viktor ^LU ; Lilljebjörn, Henrik ^LU ; Sandén, Carl ^LU ; Aab, Alar ^LU ; Hägerbrand, Karin ^LU ; Ellmark, Peter ^LU ; Borrebaeck, Carl ^LU ; Fioretos, Thoas ^LU and Lundberg, Kristina ^LU (2022) In Cancer Medicine 11(15). p.3023-3032
- Contribution to journal › Article
2021
Mark Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
Enell Smith, Karin ^LU ; Deronic, Adnan ^LU ; Hägerbrand, Karin ^LU ; Norlén, Per ^LU and Ellmark, Peter ^LU (2021) In Expert Opinion on Biological Therapy 21(12). p.1635-1646
- Contribution to journal › Scientific review

« previous
1
2
3
4
5
6
next »